OMEROS CORP OMER
Omeros Corporation ("Omeros," the "Company" or "we") is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.
Our complement-targeted product, product candidates, and therapeutic programs are primarily focused on diseases and disorders associated with the lectin and/or alternative pathways of complement. Our lectin pathway program includes inhibitors of mannan-binding lectin-associated serine protease 2 ("MASP-2") and our alternative pathway program includes inhibitors of mannan-binding lectin-associated serine protease 3 ("MASP-3").
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $73.8M | $111.8M | $29.9M | $64.8M | $41.6M |
| Cost of revenue | — | — | — | — | — | $902.0K | $865.0K | $512.0K | $1.1M | $1.4M |
| Gross profit | — | — | — | — | — | $72.9M | $110.9M | $29.4M | $63.7M | $40.2M |
| R&D | $81.3M | $119.5M | $114.9M | $112.7M | $118.8M | $107.6M | $106.3M | $89.9M | $55.6M | $50.7M |
| SG&A | $41.5M | $47.4M | $49.7M | $50.7M | $54.8M | $49.3M | $39.7M | $51.7M | $52.0M | $43.8M |
| Total operating expenses | $122.8M | $167.0M | $164.5M | $163.4M | $173.6M | $156.9M | $146.0M | $142.1M | $108.7M | $95.9M |
| Operating income | -$122.8M | -$167.0M | -$164.5M | -$163.4M | -$173.6M | -$156.9M | -$146.0M | -$112.2M | -$43.9M | -$54.3M |
| Interest expense | $960.0K | $24.7M | $30.8M | $22.7M | $19.7M | $26.8M | $22.7M | $16.3M | $11.0M | $7.8M |
| Pre-tax income | -$2.8M | -$180.3M | -$174.9M | -$182.0M | -$191.5M | -$196.4M | -$167.1M | -$139.7M | -$53.5M | -$66.7M |
| Income tax | $2.0M | $2.3M | $0 | $0 | $0 | $23.3M | $19.8M | $12.9M | $0 | $0 |
| Net income | -$3.4M | -$156.8M | -$117.8M | $47.4M | $194.2M | -$138.1M | -$84.5M | -$126.8M | -$53.5M | -$66.7M |
| EPS, basic | -0.05 | -2.70 | -1.88 | 0.76 | 3.12 | -2.41 | -1.71 | — | — | — |
| EPS, diluted | -0.05 | -2.70 | -1.88 | 0.76 | 3.12 | -2.41 | -1.71 | -2.61 | -1.17 | -1.65 |
| Shares, diluted (wtd. avg.) | $63.5M | $58.2M | $62.7M | $62.7M | $62.3M | $57.2M | $49.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.7M | $3.4M | $7.1M | $11.0M | $100.8M | $10.5M | $3.1M | $5.9M | $3.4M | $2.2M |
| Short-term investments | $162.1M | $86.7M | $164.7M | $183.9M | $56.5M | $124.5M | $57.7M | $54.6M | — | — |
| Receivables | $10.9M | $7.7M | $8.1M | $213.2M | $38.2M | $3.8M | $35.2M | $22.8M | $17.1M | $12.0M |
| Inventory | — | — | — | — | — | $1.4M | $1.1M | $88.0K | $443.0K | $1.1M |
| Total current assets | $215.7M | $134.1M | $217.9M | $443.2M | $248.0M | $151.3M | $103.7M | $89.9M | $108.4M | $60.3M |
| Property, plant and equipment | $1.8M | $2.7M | $1.9M | $1.5M | — | — | $3.8M | $3.8M | $2.1M | $1.2M |
| Total assets | $325.6M | $277.1M | $378.3M | $591.0M | $419.3M | $181.0M | $137.0M | $95.9M | $116.3M | $67.3M |
| Accounts payable | $4.8M | $5.9M | $7.7M | $6.0M | $13.4M | $4.2M | $5.3M | $6.3M | $6.7M | $2.5M |
| Short-term debt | — | — | — | — | — | — | — | $889.0K | $490.0K | $198.0K |
| Total current liabilities | $78.1M | $79.5M | $53.3M | $136.4M | $51.8M | $36.7M | $55.5M | $37.4M | $26.3M | $16.1M |
| Long-term debt | $87.9M | $164.9M | $213.2M | $315.3M | $313.5M | $236.3M | — | — | $84.1M | $79.5M |
| Retained earnings | -$913.7M | -$910.3M | -$753.5M | -$635.7M | -$683.1M | -$872.7M | -$734.6M | -$650.1M | -$523.4M | -$469.9M |
| Total equity | -$121.2M | -$182.6M | -$25.0M | $85.7M | $23.8M | -$120.8M | -$109.0M | -$100.2M | -$2.8M | -$37.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$116.1M | -$148.8M | $74.7M | -$86.5M | -$109.7M | -$100.1M | -$60.1M | -$103.7M | -$36.2M | -$51.5M |
| Depreciation and amortisation | $964.0K | $950.0K | $920.0K | $952.0K | $1.4M | — | — | — | — | — |
| Stock-based compensation | $8.2M | $10.5M | $11.7M | $14.1M | $17.6M | $14.9M | $13.8M | $11.7M | $12.7M | $13.6M |
| Capital expenditure | $65.0K | $165.0K | $426.0K | $113.0K | $277.0K | $283.0K | $334.0K | $567.0K | $350.0K | $126.0K |
| Investing cash flow | $164.5M | $82.2M | $27.5M | -$127.6M | $193.7M | -$67.0M | -$3.4M | $25.2M | -$37.6M | -$16.3M |
| Financing cash flow | -$42.2M | $62.9M | -$106.1M | $124.2M | $6.3M | $174.5M | $60.7M | $81.1M | $75.0M | $68.7M |
| Buybacks | $0 | $11.9M | $4.7M | $0 | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-010636.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |